059A Single-Dose, Open-Label, Parallel Group Study To Evaluate The Pharmacokinetics And Safety Profile Of PROELLEX (CDB-4124) In Female Subjects With Various Stages Of Impaired Renal Function And In Healthy Female Volunteers.

Trial Profile

059A Single-Dose, Open-Label, Parallel Group Study To Evaluate The Pharmacokinetics And Safety Profile Of PROELLEX (CDB-4124) In Female Subjects With Various Stages Of Impaired Renal Function And In Healthy Female Volunteers.

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Pharmacokinetics
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 03 Aug 2009 Status changed from active, no longer recruiting to suspended, according to a Repros Therapeutics media release.
    • 17 Jul 2009 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Planned end date changed from 1 Jan 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top